Cancer Cell Research (Online ISSN: 2161-2609)
 |
Current Issue
Vol.1 No.1
Article: The relationship of erbB family genes and chemosensitivity of Pemetrexed treated non-squamous NSCLC patients
by Shibo Wang, Zhuang Yu, Lianhua Cui, Hongzong Si, Kun Yang
Cancer Cell Research 2014 1(1) 1-8; published online 30 January 2014
Abstract: To investigate the relationship between the expression of the ErbB family genes and the sensitivity of non-squamous NSCLC by Pemetrexed treatment, 93 non-squamous NSCLC patients diagnosed as clinical stage ⅢB or Ⅳ and received pemetrexed-platinum chemotherapy enroll in this research. The tumor tissue and peripheral blood samples were collected for detecting ErbB family genes (EGFR\HER2\ErbB3\ErbB4) expression by immunohistochemical method and RT-PCR, and the therapeutic effect of the treatment was analyzed. The EGFR expression in tumor tissues is positively correlated with that in peripheral blood (p＝0.037), while no significant correlation was observed between HER2/ErbB3 expression in tumor tissues and that in peripheral blood (p>0.05). The expression of EGFR/HER2/ErbB3/ErbB4 shows no statistical significance between PD group and PR plus SD group (all>0.05). The mRNA level of EGFR/HER2 in blood may serve as potential indicators of chemosensitivity to pemetrexed in patients with advanced lung adenocarcinoma.
Open Access Download (free) PDF
Article: Dose-effect relationship of celecoxib， a selective Cyclooxygenase-2 Inhibitor Prevents Lymphangiogenesis in a Lewis lung carcinoma
by Xiangqian Lu, Wenjing Xiao, Xiao Li, Fangzhen Shen, Tonglin Sun
Cancer Cell Research 2014 1(1) 9-18; published online 30 January 2014
Abstract: COX-2 overexpression and lymphangiogenesis have been related to early-metastasis and poor prognosis in lung cancer. In this study, we used Lewis Lung Carcinoma cell lines were seeded in C57BL/6 mice left groin subcutaneous to establish homograft models. These models were randomly divided into four groups: control group, low-dose (30 mg.kg-1.d-1) group, medium-dose (90 mg.kg-1.d-1) group , and high dose (180 mg.kg-1.d-1) group. Then we observed the tumor-bearing survival statuses and tumor volume changes of the mice. Transplanted tumor tissues were collected after 42 days and we made a detection of COX-2, VEGF-C expression and lymphatic microvessel density by immunohistochemical staining method.Immunohistochemical staining showed that celecoxib with medium and high-dose lowered the expressions of COX-2, VEGF-C and lymphatic microvessel density (LMVD). And compared with the control group, there were significant differences (P <0.05). Though expressive levels decreased slightly, there were no significant differences between Low-dose group and control group (P>0.05). The degree of inhibition was dose-related. This study suggests that celecoxib inhibits the growth of Lewis lung tumor and lymph node metastasis by reducing expressions of COX-2 and VEGF-C and inhibiting lymphangiogenesis which is related to dosage. That provides certain experimental basis for drug development of anti-cancer lymph node metastasis in early stage and the patients’ prognosis improvement.
Open Access Download (free) PDF
Article: Prognostic Significance of TACC1 Expression in Gastric Carcinoma
by Qian Zhang, Jing Lv, Yu Li, Kewei Liu, Weiwei Qi, Wensheng Qiu
Cancer Cell Research 2014 1(1) 19-26; published online 30 January 2014
Abstract: TACC1 protein belongs to the transforming acidic coiled-coil family shown to interact with the gastric cancer. In the present study we analyzed the expression of TACC1 in gastric cancer by means of immunohistochemistry, and verified its prognostic significance by univariate and multivariate Cox analyses .In addition, the correlation between TACC1 expression and clinicopathological factors was tested by chi-square test and Fisher's exact test. The results demonstrated that TACC1 expression was linked to gastric wall invasion (T), lymph node metastasis (N), tumor node metastasis (TNM) stage and likelihood of recurrence (p<0.05). The Cox multivariate analysis indicated that the TACC1 expression was an independent indicator for shorter survival (p = 0.048). In conclusion, the study suggested that TACC1 is a favorable and independent prognostic indicator for gastric cancer.
Open Access Download (free) PDF
Article: Expression of CRM1 and Her-2/neu and Their Clinical Significance in Gastric Cancer
by Xiaoxiao Sun, Jianzhong Qiu, Weiwei Qi, Jiaxiu Liu, Jun Liang, Wensheng Qiu
Cancer Cell Research 2014 1(1) 27-36; published online 30 January 2014
Abstract: The aim of the study was to investigate the expression levels of CRM1 and Her-2/neu in gastric cancers and the corresponding normal tissues, correlation with their clinicopathological parameters and the relationship of CRM1 and Her-2/neu in the metastasis and occurrence gastric carcinoma. 135 postoperative patients were examined for CRM1 expression by immunohistochemistry and for Her-2/neu expression by fluorescence in situ hybridization (FISH). The positive expression rate of CRM1 in neoplastic tissues and adjacent gastric mucosa were 57.8% and 6.7% respectively. CRM1 levels were linked to more advanced tumor stages, poor prognosis, and likelihood of recurrence (P<0.05). The Cox multivariate analysis indicated that the CRM1 expression was an independent indicator for tumor recurrence (P=0.0048). 16 of the 135 gastric cancer specimens (11.85%) were positive for Her-2/neu, the expressions were not found in paired normal tumor-adjacent. Positive cases for Her-2/neu also had high CRM1 expression levels (P=0.0104). The current results suggest that CRM1 is expressed in gastric carcinomas and is related to poor patient outcome, and Her-2/neu has no relationship with the prognosis of GC. The relationship of CRM1 and Her-2/neu expression in gastric cancer may be benefit for selection therapeutic approaches
Open Access Download (free) PDF